Dr. Gina Elhammady, M.D.
What this data tells you about Dr. Elhammady
Dr. Gina Elhammady is a pathology - anatomic in Fort Myers, FL, with 12 years in practice. Based on federal Medicare data, Dr. Elhammady performed 39,459 Medicare services across 7,646 unique beneficiaries.
Between the years covered by Open Payments, Dr. Elhammady received a total of $570 from 6 pharmaceutical and/or device companies across 10 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pathology - anatomic. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Elhammady is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Flow cytometry, additional marker | 25,904 | $19 | $120 |
| Tissue staining for diagnosis, additional | 3,391 | $60 | $165 |
| Special stained specimen slides to examine tissue including interpretation and report | 2,121 | $56 | $161 |
| Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure | 1,930 | $240 | $565 |
| Flow cytometry technique for dna or cell analysis, first marker | 1,145 | $59 | $201 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 1,117 | $67 | $268 |
| Tissue pathology examination, moderate complexity | 983 | $49 | $233 |
| Tissue staining for diagnosis, initial | 645 | $70 | $243 |
| Preparation of tissue for examination by removing any calcium present | 508 | $14 | $48 |
| Bone marrow, smear interpretation | 447 | $55 | $253 |
| Screening examination of specimen cells, screening and interpretation | 306 | $54 | $135 |
| Microscopic genetic analysis of tumor, manual | 190 | $82 | $285 |
| Gene analysis (calreticulin), common variants | 108 | $119 | $330 |
| Gene analysis (janus kinase 2) targeted sequence analysis | 104 | $178 | $503 |
| Genetic sequencing localization, each additional procedure | 100 | $106 | $265 |
| Genetic sequencing localization, initial procedure | 99 | $141 | $435 |
| Gene analysis (mpl proto-oncogene, thrombopoietin receptor) sequence analysis of exon 10 | 80 | $170 | $482 |
| Molecular pathology procedure; physician interpretation and report | 66 | $37 | $137 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 33 | $28 | $163 |
| Translocation analysis (bcr/abl1) major breakpoint | 32 | $161 | $410 |
| Translocation analysis (bcr/abl1) minor breakpoint | 32 | $142 | $410 |
| Translocation analysis (bcr/abl1) other breakpoint | 32 | $210 | $644 |
| Gene analysis (mpl proto-oncogene, thrombopoietin receptor) for detection of common variants | 30 | $147 | $451 |
| Gene analysis (janus kinase 2) variant | 29 | $90 | $275 |
| Cell examination of specimen, selective cellular enhancement technique | 27 | $53 | $164 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
8.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Elhammady is a mixed practice specialist, with above-average Medicare volume (top 2% in FL), and high industry engagement (low-engagement, top 16%).
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Elhammady experienced with flow cytometry, additional marker?
Does Dr. Elhammady receive payments from pharmaceutical companies?
How do Dr. Elhammady's costs compare to other pathology - anatomics in Fort Myers?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology